State Street Corporation and SSGA Funds Management, Inc. acquire 7.6% stake in Ultragenyx Pharmaceutical, signaling increased interest in the pharmaceutical sector.
| Name | Ultragenyx Pharmaceutical Inc. |
|---|---|
| CIK | 0001515673 |
| Tickers | RARE |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Large accelerated filer |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 272546083 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 415-483-8800 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 1 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
State Street Corporation and SSGA Funds Management, Inc. acquire 7.6% stake in Ultragenyx Pharmaceutical, signaling increased interest in the pharmaceutical sector.
Ultragenyx Pharmaceutical Inc. completes $210 million sale of its Rare Pediatric Disease Priority Review Voucher, impacting its financial strategy.
Ultragenyx Pharmaceutical Inc. settles patent litigation with Navinta LLC, allowing for the marketing of a generic DOJOLVI starting in 2033.
Ultragenyx Pharmaceutical Inc. sells a Rare Pediatric Disease Priority Review Voucher for $203 million, enhancing its financial strength in the pharmaceutical industry.
Ultragenyx Pharmaceutical Inc. sells a Rare Pediatric Disease Priority Review Voucher for $210 million, marking a significant strategic move in the pharmaceutical sector.
1150 filing rows loaded from submissions recent; extra archives: CIK0001515673-submissions-001.json (147 filings, 2011-03-16 to 2015-07-18).
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001167557-26-000260 | 005-87964 | 261549265 | 34 | 8806 | |||
| 2026-11-10 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000093751-26-000734 | 005-87964 | 261538376 | 34 | 9326 | |||
| 2026-11-04 | 10-Q | 10-Q | 0001193125-26-445718 | 001-36276 | 261519398 | 34 | 11367635 | 1 | 1 | |
| 2026-11-03 | 8-K | 8-K | 2.01,2.02,2.05,9.01 | 0001193125-26-445342 | 001-36276 | 261517414 | 34 | 547724 | 1 | 1 |
| 2026-10-30 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100121-26-001144 | 005-87964 | 261507216 | 34 | 7321 | |||
| 2026-10-20 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001013594-26-001062 | 005-87964 | 261473765 | 34 | 19853 | |||
| 2026-10-19 | 4 | 4 | 0001193125-26-425032 | 4918 | ||||||
| 2026-10-19 | 8-K | 8-K | 8.01 | 0001193125-26-424739 | 001-36276 | 261467651 | 34 | 147881 | 1 | 1 |
| 2026-10-14 | 8-K | 8-K | 1.01 | 0001193125-26-421079 | 001-36276 | 261458414 | 34 | 149194 | 1 | 1 |
| 2026-10-07 | 8-K | 8-K | 1.01 | 0001193125-26-416251 | 001-36276 | 261445596 | 34 | 149887 | 1 | 1 |
| 2026-09-17 | 8-K | 8-K | 8.01 | 0001515673-26-000006 | 001-36276 | 261386705 | 34 | 146180 | 1 | 1 |
| 2026-09-15 | 4 | 4 | 0001193125-26-392233 | 4782 | ||||||
| 2026-09-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-009497 | 001-36276 | 261381212 | 33 | 6592 | |||
| 2026-09-08 | 4 | 4 | 0001193125-26-384878 | 5143 | ||||||
| 2026-09-02 | 8-K | 8-K | 8.01 | 0001193125-26-380165 | 001-36276 | 261354688 | 34 | 145507 | 1 | 1 |
| 2026-08-19 | 8-K | 8-K | 8.01 | 0001193125-26-357185 | 001-36276 | 261296471 | 34 | 150074 | 1 | 1 |
| 2026-08-14 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001493215-26-000161 | 005-87964 | 261276312 | 34 | 12508 | |||
| 2026-08-13 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001167557-26-000169 | 005-87964 | 261270355 | 34 | 8630 | |||
| 2026-08-11 | 8-K | 8-K | 8.01 | 0001193125-26-343525 | 001-36276 | 261260743 | 34 | 148045 | 1 | 1 |
| 2026-08-07 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000093751-26-000549 | 005-87964 | 261252387 | 34 | 8028 | |||
| 2026-08-05 | 10-Q | 10-Q | 0001193125-26-333233 | 001-36276 | 261240544 | 34 | 10751719 | 1 | 1 | |
| 2026-08-04 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-332802 | 001-36276 | 261238696 | 34 | 531302 | 1 | 1 |
| 2026-08-04 | 4 | 4 | 0001193125-26-332547 | 4718 | ||||||
| 2026-08-04 | 4 | 4 | 0001193125-26-332536 | 4754 | ||||||
| 2026-08-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007510 | 001-36276 | 261233161 | 33 | 6280 | |||
| 2026-07-31 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100121-26-001001 | 005-87964 | 261226752 | 34 | 7322 | |||
| 2026-07-31 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100119-26-001487 | 005-87964 | 261226246 | 34 | 7339 | |||
| 2026-07-30 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-003116 | 005-87964 | 261221123 | 34 | 11077 | |||
| 2026-07-06 | 4 | 4 | 0001193125-26-296128 | 4755 | ||||||
| 2026-07-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006703 | 001-36276 | 261145410 | 33 | 8433 | |||
| 2026-06-15 | 4 | 4 | 0001796536-26-000007 | 4730 | ||||||
| 2026-06-15 | 4 | 4 | 0001677455-26-000002 | 4915 | ||||||
| 2026-06-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006115 | 001-36276 | 261091573 | 33 | 4844 | |||
| 2026-06-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006073 | 001-36276 | 261090932 | 33 | 5241 | |||
| 2026-06-12 | S-8 | S-8 | 0001193125-26-269040 | 333-296732 | 261085916 | 33 | 485864 | 1 | 1 | |
| 2026-06-01 | 4 | 4 | 0001786335-26-000002 | 4755 | ||||||
| 2026-06-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-005347 | 001-36276 | 261050787 | 33 | 8329 | |||
| 2026-05-18 | 4 | 4 | 0001397266-26-000002 | 6975 | ||||||
| 2026-05-18 | 4 | 4 | 0001713070-26-000002 | 8345 | ||||||
| 2026-05-18 | 4 | 4 | 0001924797-26-000002 | 6917 | ||||||
| 2026-05-18 | 4 | 4 | 0001796536-26-000004 | 7009 | ||||||
| 2026-05-18 | 4 | 4 | 0001380022-26-000002 | 6977 | ||||||
| 2026-05-18 | 4 | 4 | 0001193125-26-229224 | 6960 | ||||||
| 2026-05-18 | 4 | 4 | 0001193125-26-229222 | 6977 | ||||||
| 2026-05-18 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-004713 | 001-36276 | 26994354 | 33 | 4727 | |||
| 2026-05-18 | 8-K | 8-K | 5.02,5.07,9.01 | 0001193125-26-228639 | 001-36276 | 26992007 | 34 | 348997 | 1 | 1 |
| 2026-05-12 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000093751-26-000302 | 005-87964 | 26967082 | 34 | 8027 | |||
| 2026-05-06 | 4 | 4 | 0001193125-26-208632 | 5121 | ||||||
| 2026-05-06 | 10-Q | 10-Q | 0001193125-26-206960 | 001-36276 | 26945079 | 34 | 9773200 | 1 | 1 | |
| 2026-05-05 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-206368 | 001-36276 | 26943007 | 34 | 456664 | 1 | 1 |
| 2026-05-04 | 4 | 4 | 0001193125-26-204402 | 4754 | ||||||
| 2026-05-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003887 | 001-36276 | 26932481 | 33 | 9896 | |||
| 2026-04-30 | DEFA14A | DEFA14A | 0001515673-26-000004 | 001-36276 | 26924962 | 34 | 1561878 | |||
| 2026-04-29 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100121-26-000786 | 005-87964 | 26915328 | 34 | 7257 | |||
| 2026-04-24 | 4 | 4 | 0001193125-26-177470 | 7529 | ||||||
| 2026-04-20 | 4 | 4 | 0001193125-26-164308 | 9954 | ||||||
| 2026-04-20 | 4 | 4 | 0001193125-26-164297 | 7569 | ||||||
| 2026-04-20 | 4 | 4 | 0001193125-26-164289 | 7571 | ||||||
| 2026-04-20 | 4 | 4 | 0001193125-26-164281 | 7468 | ||||||
| 2026-04-20 | 4 | 4 | 0001193125-26-164267 | 7485 | ||||||
| 2026-04-20 | 4 | 4 | 0001193125-26-164257 | 7513 | ||||||
| 2026-04-20 | 4 | 4 | 0001193125-26-164247 | 7505 | ||||||
| 2026-04-02 | 4 | 4 | 0001193125-26-140702 | 4753 | ||||||
| 2026-04-02 | 8-K | 8-K | 8.01 | 0001193125-26-139084 | 001-36276 | 26830778 | 34 | 154700 | 1 | 1 |
| 2026-04-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003127 | 001-36276 | 26828285 | 33 | 9895 | |||
| 2026-03-30 | 8-K | 8-K | 8.01 | 0001193125-26-130498 | 001-36276 | 26810124 | 34 | 155109 | 1 | 1 |
| 2026-03-27 | ARS | ANNUAL REPORT TO SECURITY HOLDERS | 0001308179-26-000177 | 001-36276 | 26807903 | 34 | 2336715 | |||
| 2026-03-27 | DEFA14A | DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | 0001308179-26-000175 | 001-36276 | 26807895 | 34 | 4453970 | |||
| 2026-03-27 | DEF 14A | DEFINITIVE PROXY STATEMENT | 0001308179-26-000174 | 001-36276 | 26807861 | 34 | 17118437 | 1 | 1 | |
| 2026-03-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-002574 | 005-87964 | 26805151 | 34 | 7080 | |||
| 2026-03-12 | 8-K | 8-K | 8.01 | 0001193125-26-103167 | 001-36276 | 26745798 | 34 | 162122 | 1 | 1 |
| 2026-03-10 | 4 | 4 | 0001193125-26-100309 | 5948 | ||||||
| 2026-03-10 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002450 | 001-36276 | 26739977 | 33 | 5977 | |||
| 2026-03-06 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002334 | 001-36276 | 26732393 | 33 | 5877 | |||
| 2026-03-03 | 4 | 4 | 0001193125-26-089287 | 7143 | ||||||
| 2026-03-03 | 4 | 4 | 0001193125-26-089282 | 7088 | ||||||
| 2026-03-03 | 4 | 4 | 0001193125-26-089278 | 7822 | ||||||
| 2026-03-03 | 4 | 4 | 0001193125-26-089111 | 7039 | ||||||
| 2026-03-03 | 4 | 4 | 0001193125-26-089109 | 6876 | ||||||
| 2026-03-03 | 4 | 4 | 0001193125-26-089107 | 9608 | ||||||
| 2026-03-03 | 4 | 4 | 0001193125-26-089104 | 7084 | ||||||
| 2026-03-03 | 4 | 4 | 0001193125-26-089102 | 6494 | ||||||
| 2026-03-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002108 | 001-36276 | 26715454 | 33 | 8720 | |||
| 2026-03-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002038 | 001-36276 | 26709203 | 33 | 7351 | |||
| 2026-02-23 | 8-K | 8-K | 8.01 | 0001193125-26-062568 | 001-36276 | 26662215 | 34 | 153313 | 1 | 1 |
| 2026-02-18 | 10-K | 10-K | 0001193125-26-057329 | 001-36276 | 26649716 | 34 | 19905587 | 1 | 1 | |
| 2026-02-12 | 8-K | 8-K | 2.02,2.05,9.01 | 0001193125-26-048738 | 001-36276 | 26626311 | 34 | 566511 | 1 | 1 |
| 2026-02-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-26-000545 | 005-87964 | 26602082 | 34 | 11411 | |||
| 2026-02-03 | 4 | 4 | 0001193125-26-034832 | 4616 | ||||||
| 2026-02-03 | 8-K | 8-K | 8.01 | 0001193125-26-034474 | 001-36276 | 26590217 | 34 | 174107 | 1 | 1 |
| 2026-02-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000800 | 001-36276 | 26587911 | 33 | 6667 | |||
| 2026-01-30 | 8-K | 8-K | 8.01 | 0001193125-26-030590 | 001-36276 | 26580670 | 34 | 155289 | 1 | 1 |
| 2026-01-12 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-009791 | 001-36276 | 26524690 | 34 | 227360 | 1 | 1 |
| 2026-01-05 | 4 | 4 | 0001193125-26-002410 | 4616 | ||||||
| 2026-01-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000020 | 001-36276 | 26502460 | 33 | 6668 | |||
| 2025-12-30 | 8-K | 8-K | 8.01 | 0001193125-25-337099 | 001-36276 | 251614388 | 34 | 153340 | 1 | 1 |
| 2025-12-30 | 4 | 4 | 0001193125-25-336619 | 4994 | ||||||
| 2025-12-29 | 8-K | 8-K | 8.01 | 0001193125-25-332422 | 001-36276 | 251603439 | 34 | 157987 | 1 | 1 |
| 2025-12-11 | 4 | 4 | 0001193125-25-315460 | 4617 | ||||||
| 2025-12-10 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-010053 | 001-36276 | 251562018 | 33 | 5985 | |||
| 2025-11-05 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-002839 | 005-87964 | 251452782 | 34 | 11257 | |||
| 2025-11-05 | 10-Q | 10-Q | 0001193125-25-265126 | 001-36276 | 251451036 | 34 | 11457593 | 1 | 1 | |
| 2025-11-04 | 8-K | 8-K | 1.01,2.02,9.01 | 0001193125-25-264707 | 001-36276 | 251449182 | 34 | 570374 | 1 | 1 |
| 2025-10-30 | 8-K | 8-K | 8.01 | 0001193125-25-257538 | 001-36276 | 251432379 | 34 | 170873 | 1 | 1 |
| 2025-10-14 | 4 | 4 | 0001193125-25-238708 | 4781 | ||||||
| 2025-09-19 | 4 | 4 | 0001193125-25-209387 | 4803 | ||||||
| 2025-09-12 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-007039 | 001-36276 | 251311709 | 33 | 4600 | |||
| 2025-09-12 | 4 | 4 | 0001677455-25-000005 | 4771 | ||||||
| 2025-09-08 | 8-K | 8-K | 8.01 | 0000950170-25-113553 | 001-36276 | 251300180 | 34 | 165507 | 1 | 1 |
| 2025-09-08 | 4 | 4 | 0000950170-25-113446 | 4996 | ||||||
| 2025-08-18 | 8-K | 8-K | 8.01 | 0000950170-25-109570 | 001-36276 | 251226342 | 34 | 154042 | 1 | 1 |
| 2025-08-06 | 10-Q | 10-Q | 0000950170-25-103290 | 001-36276 | 251186557 | 34 | 11235627 | 1 | 1 | |
| 2025-08-05 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-103026 | 001-36276 | 251184960 | 34 | 537180 | 1 | 1 |
| 2025-07-31 | 8-K | 8-K | 8.01 | 0000950170-25-100918 | 001-36276 | 251171856 | 34 | 154524 | 1 | 1 |
| 2025-07-18 | S-8 | S-8 | 0000950170-25-096912 | 333-288764 | 251134457 | 33 | 566182 | 1 | 1 | |
| 2025-07-11 | 8-K | 8-K | 8.01 | 0000950170-25-095334 | 001-36276 | 251119450 | 34 | 155671 | 1 | 1 |
| 2025-07-09 | 8-K | 8-K | 8.01 | 0000950170-25-094806 | 001-36276 | 251113928 | 34 | 156162 | 1 | 1 |
| 2025-06-27 | 8-K | 8-K | 8.01 | 0000950170-25-090616 | 001-36276 | 251082301 | 34 | 152788 | 1 | 1 |
| 2025-06-23 | 4 | 4 | 0000950170-25-088878 | 4329 | ||||||
| 2025-06-20 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004490 | 001-36276 | 251061244 | 33 | 4750 | |||
| 2025-05-19 | 4 | 4 | 0000950170-25-074669 | 6806 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074667 | 6823 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074666 | 6872 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074665 | 6850 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074664 | 6838 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074662 | 6840 | ||||||
| 2025-05-19 | 4 | 4 | 0000950170-25-074661 | 6780 | ||||||
| 2025-05-19 | 8-K | 8-K | 5.02,5.07,9.01 | 0000950170-25-074529 | 001-36276 | 25964934 | 34 | 341227 | 1 | 1 |
| 2025-05-07 | 10-Q | 10-Q | 0000950170-25-064726 | 001-36276 | 25918720 | 34 | 10005071 | 1 | 1 | |
| 2025-05-06 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-064473 | 001-36276 | 25917360 | 34 | 468317 | 1 | 1 |
| 2025-05-05 | 4 | 4 | 0000950170-25-063792 | 6391 | ||||||
| 2025-04-24 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-001563 | 005-87964 | 25863911 | 34 | 11020 | |||
| 2025-03-28 | ARS | ANNUAL REPORT TO SECURITY HOLDERS | 0001308179-25-000298 | 001-36276 | 25787445 | 34 | 9739612 | |||
| 2025-03-28 | DEFA14A | DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | 0001308179-25-000297 | 001-36276 | 25787418 | 34 | 4380974 | |||
| 2025-03-28 | DEF 14A | DEFINITIVE PROXY STATEMENT | 0001308179-25-000296 | 001-36276 | 25787411 | 34 | 15243268 | 1 | 1 | |
| 2025-03-10 | 4 | 4 | 0000950170-25-036056 | 5295 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032802 | 8476 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032798 | 6850 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032794 | 11228 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032785 | 12783 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032779 | 13045 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032773 | 11152 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032767 | 10555 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032764 | 10995 | ||||||
| 2025-03-04 | 4 | 4 | 0000950170-25-032750 | 7388 | ||||||
| 2025-03-03 | 4 | 4 | 0000950170-25-030639 | 10269 | ||||||
| 2025-02-28 | 144 | xsl144X01/primary_doc.xml | 0002007317-25-000222 | 001-36276 | 25690266 | 33 | 7143 | |||
| 2025-02-27 | 144 | xsl144X01/primary_doc.xml | 0001972362-25-000193 | 001-36276 | 25680551 | 33 | 7249 | |||
| 2025-02-19 | 10-K | 10-K | 0000950170-25-023312 | 001-36276 | 25641376 | 34 | 20817803 | 1 | 1 | |
| 2025-02-13 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-019854 | 001-36276 | 25620091 | 34 | 630918 | 1 | 1 |
| 2025-02-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001020066-25-000013 | 005-87964 | 25613367 | 34 | 13561 | |||
| 2025-02-10 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902219-25-000076 | 005-87964 | 25604166 | 34 | 15260 | |||
| 2025-01-13 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-004587 | 001-36276 | 25524970 | 34 | 234203 | 1 | 1 |
| 2024-12-31 | 4 | 4 | 0000950170-24-141485 | 5834 | ||||||
| 2024-12-30 | 144 | xsl144X01/primary_doc.xml | 0001971857-24-000911 | 001-36276 | 241590233 | 33 | 4922 | |||
| 2024-12-19 | 8-K | 8-K | 8.01 | 0000950170-24-138467 | 001-36276 | 241563491 | 34 | 156557 | 1 | 1 |
| 2024-12-19 | 8-K | 8-K | 8.01 | 0000950170-24-138250 | 001-36276 | 241561054 | 34 | 156872 | 1 | 1 |
| 2024-12-11 | 4 | 4 | 0000950170-24-135525 | 4839 | ||||||
| 2024-12-11 | 4 | 4 | 0000950170-24-135521 | 7096 | ||||||
| 2024-12-10 | 144 | xsl144X01/primary_doc.xml | 0001971857-24-000811 | 001-36276 | 241538598 | 33 | 4284 | |||
| 2024-11-14 | SC 13G/A | ULTRAGENYX PHARMACEUTICAL INC. | 0000902664-24-006498 | 005-87964 | 241456997 | 34 | 63459 | |||
| 2024-11-12 | 8-K | 8-K | 8.01 | 0000950170-24-124458 | 001-36276 | 241442751 | 34 | 157682 | 1 | 1 |
| 2024-11-06 | 10-Q | 10-Q | 0000950170-24-121679 | 001-36276 | 241428784 | 34 | 10047829 | 1 | 1 | |
| 2024-11-05 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-121459 | 001-36276 | 241427473 | 34 | 468665 | 1 | 1 |
| 2024-10-11 | 4 | 4 | 0000950170-24-114378 | 4801 | ||||||
| 2024-10-07 | 8-K | 8-K | 8.01 | 0000950170-24-113085 | 001-36276 | 241356217 | 34 | 154245 | 1 | 1 |
| 2024-10-03 | 8-K | 8-K | 8.01 | 0000950170-24-112402 | 001-36276 | 241352008 | 34 | 156696 | 1 | 1 |
| 2024-09-18 | 4 | 4 | 0000950170-24-107677 | 5005 | ||||||
| 2024-09-05 | 4 | 4 | 0000950170-24-103811 | 5920 | ||||||
| 2024-09-05 | 4 | 4 | 0000950170-24-103807 | 5015 | ||||||
| 2024-09-03 | 144 | xsl144X01/primary_doc.xml | 0002002698-24-000359 | 001-36276 | 241274656 | 33 | 4887 | |||
| 2024-08-07 | 4 | 4 | 0000950170-24-092608 | 6109 | ||||||
| 2024-08-06 | 144 | xsl144X01/primary_doc.xml | 0002007317-24-000519 | 001-36276 | 241179796 | 33 | 4287 | |||
| 2024-08-02 | 10-Q | 10-Q | 0000950170-24-089488 | 001-36276 | 241168206 | 34 | 9776674 | 1 | 1 | |
| 2024-08-01 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-089263 | 001-36276 | 241166640 | 34 | 469997 | 1 | 1 |
| 2024-07-17 | 8-K | 8-K | 8.01 | 0000950170-24-084254 | 001-36276 | 241122259 | 34 | 161690 | 1 | 1 |
| 2024-07-12 | S-8 | S-8 | 0000950170-24-083195 | 333-280776 | 241114486 | 33 | 389332 | |||
| 2024-07-03 | 4 | 4 | 0000950170-24-081302 | 4335 | ||||||
| 2024-07-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-005193 | 001-36276 | 241095130 | 33 | 5446 | |||
| 2024-06-21 | 8-K | 8-K | 5.02,5.07,9.01 | 0000950170-24-076222 | 001-36276 | 241060163 | 34 | 325860 | 1 | 1 |
| 2024-06-20 | 4 | 4 | 0000950170-24-075491 | 6847 | ||||||
| 2024-06-20 | 4 | 4 | 0000950170-24-075489 | 6845 | ||||||
| 2024-06-20 | 4 | 4 | 0000950170-24-075488 | 6830 | ||||||
| 2024-06-20 | 4 | 4 | 0000950170-24-075487 | 6857 | ||||||
| 2024-06-20 | 4 | 4 | 0000950170-24-075486 | 6787 | ||||||
| 2024-06-20 | 4 | 4 | 0000950170-24-075485 | 6879 | ||||||
| 2024-06-20 | 4 | 4 | 0000950170-24-075483 | 6813 | ||||||
| 2024-06-17 | 8-K | 8-K | 1.01,9.01 | 0001193125-24-162003 | 001-36276 | 241046909 | 34 | 638491 | 1 | 1 |
| 2024-06-14 | 424B5 | 424B5 | 0001193125-24-161716 | 333-277226 | 241045921 | 33 | 601902 | |||
| 2024-06-12 | 4 | 4 | 0000950170-24-072621 | 4782 | ||||||
| 2024-06-12 | 424B5 | 424B5 | 0001193125-24-160052 | 333-277226 | 241039350 | 33 | 577117 | |||
| 2024-06-12 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-004699 | 001-36276 | 241039229 | 33 | 5290 | |||
| 2024-06-12 | 8-K | 8-K | 8.01 | 0000950170-24-072414 | 001-36276 | 241038384 | 34 | 153587 | 1 | 1 |
| 2024-06-12 | 8-K | 8-K | 8.01 | 0000950170-24-072119 | 001-36276 | 241037098 | 34 | 160844 | 1 | 1 |
| 2024-06-10 | 4 | 4 | 0000950170-24-071548 | 4598 | ||||||
| 2024-06-10 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-004584 | 001-36276 | 241033818 | 33 | 4757 | |||
| 2024-06-10 | UPLOAD | filename1.pdf | 0000000000-24-006612 | 001-36276 | 39582 | |||||
| 2024-05-30 | 8-K | 8-K | 8.01,9.01 | 0000950170-24-066553 | 001-36276 | 241005133 | 34 | 162871 | 1 | 1 |
| 2024-05-17 | CORRESP | filename1.htm | 0001193125-24-141579 | 44304 | ||||||
| 2024-05-03 | 4 | 4 | 0000950170-24-052788 | 4794 | ||||||
| 2024-05-03 | 10-Q | 10-Q | 0000950170-24-052346 | 001-36276 | 24910122 | 34 | 8314984 | 1 | 1 | |
| 2024-05-02 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-052052 | 001-36276 | 24908012 | 34 | 370210 | 1 | 1 |
| 2024-04-26 | ARS | ULTRAGENYX PHARMACEUTICAL INC. - ARS | 0001308179-24-000611 | 001-36276 | 24884454 | 34 | 2147498 | |||
| 2024-04-26 | DEFA14A | ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A | 0001308179-24-000610 | 001-36276 | 24884423 | 34 | 791135 | |||
| 2024-04-26 | DEF 14A | ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A | 0001308179-24-000609 | 001-36276 | 24884408 | 34 | 5157641 | 1 | 1 | |
| 2024-04-22 | UPLOAD | filename1.pdf | 0000000000-24-004406 | 001-36276 | 43464 | |||||
| 2024-04-19 | 4 | 4 | 0000950170-24-046055 | 4793 | ||||||
| 2024-04-18 | 4 | 4 | 0000950170-24-045670 | 4858 | ||||||
| 2024-04-15 | 8-K | 8-K | 8.01,9.01 | 0000950123-24-003302 | 001-36276 | 24843155 | 34 | 175096 | 1 | 1 |
| 2024-03-12 | 4 | 4 | 0000950170-24-029780 | 5135 | ||||||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000386 | 001-36276 | 24739627 | 33 | 10158 | |||
| 2024-03-11 | 4 | 4 | 0000950170-24-029040 | 8101 | ||||||
| 2024-03-07 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-001996 | 001-36276 | 24730165 | 33 | 5908 | |||
| 2024-03-05 | 4 | 4 | 0000950170-24-026672 | 7724 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026666 | 10669 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026661 | 12098 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026652 | 10614 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026648 | 12145 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026641 | 13183 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026635 | 11792 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026629 | 10636 | ||||||
| 2024-03-05 | 4 | 4 | 0000950170-24-026625 | 11386 | ||||||
| 2024-02-21 | S-3ASR | S-3ASR | 0001193125-24-041577 | 333-277226 | 24660772 | 33 | 1207105 | |||
| 2024-02-21 | 10-K | 10-K | 0000950170-24-017879 | 001-36276 | 24659279 | 34 | 17403760 | 1 | 1 | |
| 2024-02-15 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-015856 | 001-36276 | 24643754 | 34 | 495500 | 1 | 1 |
| 2024-02-14 | SC 13G/A | rare13gadec23.txt | 0000080255-24-000711 | 005-87964 | 34 | 6646 | ||||
| 2024-02-14 | SC 13G/A | ULTRAGENYX PHARMACEUTICAL INC. | 0000902664-24-001572 | 005-87964 | 24632370 | 34 | 62905 | |||
| 2024-02-13 | SC 13G/A | SCHEDULE 13G/A | 0001104659-24-022166 | 005-87964 | 24629838 | 34 | 13018 | |||
| 2024-02-13 | SC 13G | rare_13g.htm | 0000908834-24-000059 | 005-87964 | 24625345 | 34 | 55616 | |||
| 2024-02-08 | 4 | FORM 4 SUBMISSION | 0001209191-24-002989 | 6283 | ||||||
| 2024-02-08 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-24-000136 | 005-87964 | 24607353 | 34 | 37498 | |||
| 2024-02-07 | 144 | xsl144X01/primary_doc.xml | 0002007317-24-000082 | 001-36276 | 24604980 | 33 | 8124 | |||
| 2024-01-29 | SC 13G/A | us90400d1081_012924.txt | 0001086364-24-005180 | 005-87964 | 24573156 | 34 | 13695 | |||
| 2024-01-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-002655 | 001-36276 | 24518174 | 34 | 732186 | 1 | 1 |
| 2024-01-02 | 4 | FORM 4 SUBMISSION | 0001209191-24-000071 | 6517 | ||||||
| 2024-01-02 | 4 | FORM 4 SUBMISSION | 0001209191-24-000070 | 9330 | ||||||
| 2023-12-29 | 144 | xsl144X01/primary_doc.xml | 0002002698-23-000203 | 001-36276 | 231528338 | 33 | 10832 | |||
| 2023-12-21 | 8-K | 8-K | 5.03,9.01 | 0000950170-23-072192 | 001-36276 | 231505266 | 34 | 292788 | 1 | 1 |
| 2023-11-03 | 10-Q | 10-Q | 0000950170-23-058427 | 001-36276 | 231373923 | 34 | 11000594 | 1 | 1 | |
| 2023-11-02 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-058240 | 001-36276 | 231372566 | 34 | 567614 | 1 | 1 |
| 2023-10-24 | 4 | FORM 4 SUBMISSION | 0001209191-23-053487 | 9284 | ||||||
| 2023-10-23 | 4 | FORM 4 SUBMISSION | 0001209191-23-053351 | 10423 | ||||||
| 2023-10-23 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-004591 | 001-36276 | 231340396 | 33 | 4664 | |||
| 2023-10-23 | 8-K | 8-K | 1.01,9.01 | 0001193125-23-260305 | 001-36276 | 231338472 | 34 | 548493 | 1 | 1 |
| 2023-10-20 | 424B5 | 424B5 | 0001193125-23-259557 | 333-253008 | 231335938 | 33 | 520939 | |||
| 2023-10-19 | 144 | xsl144X01/primary_doc.xml | 0001971857-23-000764 | 001-36276 | 231335182 | 33 | 4205 | |||
| 2023-10-19 | FWP | FWP | 0001193125-23-258745 | 333-253008 | 231333148 | 34 | 35576 | |||
| 2023-10-17 | 424B5 | 424B5 | 0001193125-23-257669 | 333-253008 | 231329735 | 33 | 475885 | |||
| 2023-10-16 | 8-K | 8-K | 2.02,7.01,8.01,9.01 | 0001193125-23-256537 | 001-36276 | 231326251 | 34 | 2690608 | 1 | 1 |
| 2023-10-10 | 4 | FORM 4 SUBMISSION | 0001209191-23-052466 | 7470 | ||||||
| 2023-10-10 | 3 | FORM 3 SUBMISSION | 0001209191-23-052462 | 7415 | ||||||
| 2023-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-23-050841 | 6751 | ||||||
| 2023-09-29 | 4 | FORM 4 SUBMISSION | 0001209191-23-050840 | 6733 | ||||||
| 2023-09-11 | 4 | FORM 4 SUBMISSION | 0001209191-23-048905 | 10460 | ||||||
| 2023-09-11 | SC 13G/A | SCHEDULE 13G/A | 0001104659-23-099626 | 005-87964 | 231247415 | 34 | 12938 | |||
| 2023-09-08 | 8-K | 8-K | 5.02,9.01 | 0000950170-23-047138 | 001-36276 | 231243696 | 34 | 214068 | 1 | 1 |
| 2023-09-07 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-003831 | 001-36276 | 231242961 | 33 | 6638 | |||
| 2023-09-06 | 4 | FORM 4 SUBMISSION | 0001209191-23-048491 | 5214 | ||||||
| 2023-09-06 | 4 | FORM 4 SUBMISSION | 0001209191-23-048489 | 7411 | ||||||
| 2023-09-05 | 144 | xsl144X01/primary_doc.xml | 0001972362-23-000777 | 001-36276 | 231237386 | 33 | 7793 | |||
| 2023-08-04 | 10-Q | 10-Q | 0000950170-23-038173 | 001-36276 | 231141515 | 34 | 11898403 | 1 | 1 | |
| 2023-08-03 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-037962 | 001-36276 | 231139980 | 34 | 625725 | 1 | 1 |
| 2023-07-12 | 8-K | 8-K | 5.02,7.01,9.01 | 0000950170-23-032604 | 001-36276 | 231083290 | 34 | 342996 | 1 | 1 |
| 2023-07-06 | 8-K | 8-K | 7.01,8.01,9.01 | 0000950170-23-031902 | 001-36276 | 231072149 | 34 | 230731 | 1 | 1 |
| 2023-06-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-002004 | 001-36276 | 231062077 | 33 | 5272 | |||
| 2023-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-040269 | 4736 | ||||||
| 2023-06-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-038885 | 5080 | ||||||
| 2023-06-13 | 8-K | 8-K | 5.02,5.07 | 0000950170-23-027644 | 001-36276 | 231010829 | 34 | 203324 | 1 | 1 |
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035692 | 7088 | ||||||
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035691 | 8964 | ||||||
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035690 | 8930 | ||||||
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035689 | 7120 | ||||||
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035688 | 7149 | ||||||
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035687 | 7153 | ||||||
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035686 | 7137 | ||||||
| 2023-06-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-001429 | 001-36276 | 231002629 | 33 | 4588 | |||
| 2023-06-08 | S-8 | S-8 | 0000950170-23-027029 | 333-272518 | 231002415 | 33 | 590080 | |||
| 2023-06-05 | 8-K | 8-K | 7.01,8.01,9.01 | 0000950170-23-026375 | 001-36276 | 23992745 | 34 | 264005 | 1 | 1 |
| 2023-05-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-030931 | 5213 | ||||||
| 2023-05-18 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-000769 | 001-36276 | 23936678 | 33 | 5898 | |||
| 2023-05-17 | 8-K | 8-K | 8.01 | 0000950170-23-022610 | 001-36276 | 23929687 | 34 | 160660 | 1 | 1 |
| 2023-05-10 | 4 | FORM 4 SUBMISSION | 0001209191-23-028585 | 7347 | ||||||
| 2023-05-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-027601 | 5136 | ||||||
| 2023-05-05 | 10-Q | 10-Q | 0000950170-23-018017 | 001-36276 | 23890460 | 34 | 10093394 | 1 | 1 | |
| 2023-05-04 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-000410 | 001-36276 | 23890636 | 33 | 7584 | |||
| 2023-05-04 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-017852 | 001-36276 | 23888738 | 34 | 458441 | 1 | 1 |
| 2023-05-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-026692 | 7681 | ||||||
| 2023-05-02 | 3 | FORM 3 SUBMISSION | 0001209191-23-026682 | 15847 | ||||||
| 2023-04-24 | DEFA14A | ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A | 0001308179-23-000758 | 001-36276 | 23840506 | 34 | 818411 | |||
| 2023-04-24 | DEF 14A | ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A | 0001308179-23-000757 | 001-36276 | 23840493 | 34 | 4954107 | 1 | 1 | |
| 2023-04-18 | 4 | FORM 4 SUBMISSION | 0001209191-23-024685 | 6852 | ||||||
| 2023-03-23 | 8-K | 8-K | 5.02 | 0000950170-23-009543 | 001-36276 | 23756944 | 34 | 160832 | 1 | 1 |
| 2023-03-14 | 8-K | 8-K | 5.02 | 0000950170-23-007720 | 001-36276 | 23729282 | 34 | 163989 | 1 | 1 |
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016053 | 6728 | ||||||
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016047 | 11245 | ||||||
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016046 | 12932 | ||||||
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016045 | 11178 | ||||||
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016043 | 12954 | ||||||
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016042 | 12936 | ||||||
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016041 | 12532 | ||||||
| 2023-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-016039 | 11213 | ||||||
| 2023-03-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-014502 | 5031 | ||||||
| 2023-02-17 | S-8 | S-8 | 0000950170-23-003098 | 333-269840 | 23639708 | 33 | 286097 | |||
| 2023-02-17 | 10-K | 10-K | 0000950170-23-003096 | 001-36276 | 23639697 | 34 | 22020040 | 1 | 1 | |
| 2023-02-16 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-003048 | 001-36276 | 23638590 | 34 | 1156963 | 1 | 1 |
| 2023-02-14 | SC 13G/A | rare13gadec22.txt | 0000080255-23-002627 | 005-87964 | 34 | 6810 | ||||
| 2023-02-14 | SC 13G | ULTRAGENYX PHARMACEUTICAL INC. | 0000902664-23-001730 | 005-87964 | 23623879 | 34 | 66878 | |||
| 2023-02-09 | SC 13G/A | SCHEDULE 13G/A | 0001104659-23-017168 | 005-87964 | 23604556 | 34 | 12935 | |||
| 2023-02-06 | SC 13G | SEC SCHEDULE 13G | 0000846087-23-000186 | 005-87964 | 23590231 | 34 | 37580 | |||
| 2023-02-03 | SC 13G | us90400d1081_020323.txt | 0001306550-23-007094 | 005-87964 | 23584747 | 34 | 13450 | |||
| 2023-01-10 | SC 13G/A | form774.htm | 0001623632-23-000009 | 005-87964 | 23519767 | 34 | 174215 | |||
| 2023-01-06 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-23-000338 | 001-36276 | 23515319 | 34 | 758221 | 1 | 1 |
| 2023-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-23-000276 | 6531 | ||||||
| 2022-12-22 | 4 | FORM 4 SUBMISSION | 0001209191-22-062400 | 5217 | ||||||
| 2022-12-09 | SC 13G/A | SEC SCHEDULE 13G | 0001562230-22-000126 | 005-87964 | 221454459 | 34 | 18316 | |||
| 2022-11-10 | 8-K | 8-K | 5.02 | 0001193125-22-282661 | 001-36276 | 221377676 | 34 | 137986 | 1 | 1 |
| 2022-11-03 | 10-Q | 10-Q | 0000950170-22-021366 | 001-36276 | 221355511 | 34 | 12536709 | 1 | 1 | |
| 2022-11-02 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-021238 | 001-36276 | 221354181 | 34 | 1150714 | 1 | 1 |
| 2022-10-28 | 8-K | 8-K | 5.07 | 0000950170-22-020460 | 001-36276 | 221341953 | 34 | 163919 | 1 | 1 |
| 2022-10-17 | 4 | FORM 4 SUBMISSION | 0001209191-22-053884 | 5021 | ||||||
| 2022-10-14 | 4 | FORM 4 SUBMISSION | 0001209191-22-053647 | 4956 | ||||||
| 2022-09-19 | 4 | FORM 4 SUBMISSION | 0001209191-22-050670 | 5118 | ||||||
| 2022-09-15 | 8-K | 8-K | 5.02 | 0000950170-22-018538 | 001-36276 | 221245873 | 34 | 177160 | 1 | 1 |
| 2022-09-08 | 4 | FORM 4 SUBMISSION | 0001209191-22-049222 | 5305 | ||||||
| 2022-08-10 | SC 13G/A | rare13gajul22.txt | 0000080255-22-002502 | 005-87964 | 34 | 6806 | ||||
| 2022-07-29 | 10-Q | 10-Q | 0000950170-22-013411 | 001-36276 | 221116640 | 34 | 12724550 | 1 | 1 | |
| 2022-07-28 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-013372 | 001-36276 | 221115301 | 34 | 1111545 | 1 | 1 |
| 2022-07-18 | 8-K | 8-K | 1.01,2.01,7.01,8.01,9.01 | 0000950170-22-012761 | 001-36276 | 221089293 | 34 | 254540 | 1 | 1 |
| 2022-07-14 | 8-K | 8-K | 1.01,8.01,9.01 | 0000950170-22-012669 | 001-36276 | 221082251 | 34 | 747886 | 1 | 1 |
| 2022-06-29 | 4 | FORM 4 SUBMISSION | 0001209191-22-039770 | 7155 | ||||||
| 2022-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-039568 | 7107 | ||||||
| 2022-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-039567 | 7114 | ||||||
| 2022-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-039566 | 7122 | ||||||
| 2022-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-039565 | 7134 | ||||||
| 2022-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-039564 | 7057 | ||||||
| 2022-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-039562 | 7090 | ||||||
| 2022-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-22-039561 | 7124 | ||||||
| 2022-06-27 | 8-K | 8-K | 5.07 | 0000950170-22-012192 | 001-36276 | 221044684 | 34 | 186349 | 1 | 1 |
| 2022-06-22 | 4 | FORM 4 SUBMISSION | 0001209191-22-038774 | 5043 | ||||||
| 2022-05-17 | 8-K | 8-K | 8.01,9.01 | 0000950170-22-010158 | 001-36276 | 22932298 | 34 | 262108 | 1 | 1 |
| 2022-05-06 | 10-Q | 10-Q | 0000950170-22-007940 | 001-36276 | 22898139 | 34 | 9017985 | 1 | 1 | |
| 2022-05-05 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-007796 | 001-36276 | 22896039 | 34 | 949369 | 1 | 1 |
| 2022-04-28 | DEFA14A | ULTRAGENYX PHARMACEUTICAL INC. - DEFA14A | 0001308179-22-000295 | 001-36276 | 22866643 | 34 | 808243 | |||
| 2022-04-28 | DEF 14A | ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A | 0001308179-22-000294 | 001-36276 | 22866616 | 34 | 2279945 | |||
| 2022-04-22 | 4 | FORM 4 SUBMISSION | 0001209191-22-025279 | 7377 | ||||||
| 2022-04-22 | 3 | FORM 3 SUBMISSION | 0001209191-22-025278 | 7285 | ||||||
| 2022-04-22 | 8-K | 8-K | 5.02 | 0000950170-22-005981 | 001-36276 | 22843426 | 34 | 166890 | 1 | 1 |
| 2022-04-19 | 4 | FORM 4 SUBMISSION | 0001209191-22-024699 | 4961 | ||||||
| 2022-03-15 | 4 | FORM 4 SUBMISSION | 0001209191-22-018829 | 5249 | ||||||
| 2022-03-09 | SC 13G/A | us90400d1081_030922.txt | 0000834237-22-008958 | 005-87964 | 22726322 | 34 | 12569 | |||
| 2022-03-08 | 4 | FORM 4 SUBMISSION | 0001209191-22-016931 | 5197 | ||||||
| 2022-03-08 | 4 | FORM 4 SUBMISSION | 0001209191-22-016930 | 6976 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015833 | 11156 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015830 | 9264 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015823 | 9394 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015819 | 9541 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015815 | 9585 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015811 | 9656 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015806 | 9351 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015802 | 9357 | ||||||
| 2022-03-03 | 4 | FORM 4 SUBMISSION | 0001209191-22-015799 | 10127 | ||||||
| 2022-02-15 | S-8 | S-8 | 0001564590-22-005225 | 333-262751 | 22639543 | 33 | 202053 | |||
| 2022-02-15 | 10-K | 10-K | 0000950170-22-001284 | 001-36276 | 22639426 | 34 | 18379698 | 1 | 1 | |
| 2022-02-14 | SC 13G/A | form69.htm | 0001623632-22-000251 | 005-87964 | 22630100 | 34 | 278559 | |||
| 2022-02-14 | SC 13G/A | rare13gadec21.txt | 0000080255-22-002104 | 005-87964 | 34 | 6785 | ||||
| 2022-02-11 | SC 13G/A | SEC SCHEDULE 13G | 0001562230-22-000068 | 005-87964 | 22617870 | 34 | 18225 | |||
| 2022-02-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-001079 | 001-36276 | 22614017 | 34 | 1116186 | 1 | 1 |
| 2022-02-10 | SC 13G/A | SCHEDULE 13G/A | 0001104659-22-018771 | 005-87964 | 22611077 | 34 | 12930 | |||
| 2022-02-03 | SC 13G/A | us90400d1081_020322.txt | 0000834237-22-006251 | 005-87964 | 22589109 | 34 | 13438 | |||
| 2022-02-01 | 5 | FORM 5 SUBMISSION | 0001209191-22-005840 | 4866 | ||||||
| 2022-02-01 | 5 | FORM 5 SUBMISSION | 0001209191-22-005839 | 5724 | ||||||
| 2022-02-01 | 4 | FORM 4 SUBMISSION | 0001209191-22-005838 | 4956 | ||||||
| 2022-01-10 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-22-000187 | 001-36276 | 22519817 | 34 | 275086 | 1 | 1 |
| 2022-01-07 | 8-K | 8-K | 8.01,9.01 | 0000950170-22-000122 | 001-36276 | 22516468 | 34 | 287577 | 1 | 1 |
| 2021-11-03 | 10-Q | 10-Q | 0000950170-21-002687 | 001-36276 | 211372886 | 34 | 11091509 | 1 | 1 | |
| 2021-11-02 | 8-K | 8-K | 2.02,9.01 | 0000950170-21-002657 | 001-36276 | 211371471 | 34 | 1085423 | 1 | 1 |
| 2021-10-26 | SC 13D/A | SC 13D/A | 0001193125-21-308036 | 43425 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060765 | 4956 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060760 | 4863 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060759 | 4979 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060756 | 6508 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060754 | 4949 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060752 | 4894 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060749 | 5724 | ||||||
| 2021-10-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-060748 | 4993 | ||||||
| 2021-10-14 | 4 | FORM 4 SUBMISSION | 0001209191-21-060504 | 7253 | ||||||
| 2021-10-08 | SC 13G/A | SEC SCHEDULE 13G | 0001422848-21-000160 | 005-87964 | 211314914 | 34 | 18170 | |||
| 2021-10-07 | 8-K | 8-K | 8.01,9.01 | 0000950170-21-002049 | 001-36276 | 211311099 | 34 | 1117085 | 1 | 1 |
| 2021-10-01 | 4 | FORM 4 SUBMISSION | 0001209191-21-058365 | 7234 | ||||||
| 2021-09-27 | 8-K | 8-K | 8.01,9.01 | 0000950170-21-001889 | 001-36276 | 211279028 | 34 | 1112978 | 1 | 1 |
| 2021-09-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-055362 | 8861 | ||||||
| 2021-09-02 | 4 | FORM 4 SUBMISSION | 0001209191-21-054542 | 15182 | ||||||
| 2021-08-12 | 4 | FORM 4 SUBMISSION | 0001209191-21-051182 | 001-38942 | 211168662 | 34 | 7269 | |||
| 2021-08-12 | SC 13D/A | SC 13D/A | 0001193125-21-244861 | 43345 | ||||||
| 2021-08-03 | 10-Q | 10-Q | 0001564590-21-039879 | 001-36276 | 211137295 | 34 | 11460794 | 1 | 1 | |
| 2021-08-02 | 8-K | 8-K | 2.02,9.01 | 0000950170-21-000648 | 001-36276 | 211136143 | 34 | 1320036 | 1 | 1 |
| 2021-07-08 | 4 | FORM 4 SUBMISSION | 0001209191-21-045972 | 4863 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044165 | 7242 | ||||||
| 2021-06-30 | 3 | FORM 3 SUBMISSION | 0001209191-21-044164 | 7423 | ||||||
| 2021-06-30 | 8-K | 8-K | 5.02 | 0000950170-21-000408 | 001-36276 | 211060512 | 34 | 161805 | 1 | 1 |
One latest value per concept from companyfacts (370 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 101.92M | 2026-10-29 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 3.40B | 2025-06-30 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 45.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 166.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 1.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 242.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 136.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | USD | -2.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | USD | 1.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -1.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 4.55B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock | USD | 6.74M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 98.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition | USD | -1.26M | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalWarrantIssued | Adjustments to Additional Paid in Capital, Warrant Issued | USD | 6.74M | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-11 | 0001564590-14-003472 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 98.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | AllowanceForDoubtfulAccountsReceivable | Accounts Receivable, Allowance for Credit Loss | USD | 80.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AllowanceForDoubtfulAccountsReceivableWriteOffs | Accounts Receivable, Allowance for Credit Loss, Writeoff | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 17.4 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | Assets | Assets | USD | 1.19B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 544.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 342.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AssetsFairValueDisclosureRecurring | Assets, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) | USD | 223.65M | 2017-12-31 | 2017 | FY | 10-K | 2018-02-21 | 0001564590-18-002535 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 2.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 319.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AvailableForSaleSecurities | Available-for-sale Securities | USD | 918.63M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0000950170-21-002687 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | USD | 96,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0000950170-21-002687 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | USD | 123,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0000950170-21-002687 | |
| us-gaap | AvailableForSaleSecuritiesAmortizedCost | Available-for-sale Securities, Amortized Cost Basis | USD | 918.66M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0000950170-21-002687 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 317.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 116.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesNoncurrent | Debt Securities, Available-for-sale, Noncurrent | USD | 135.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | AvailableForSaleSecuritiesGrossRealizedGainLossNet | Available-for-sale Securities, Gross Realized Gain (Loss) | USD | 0 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-03 | 0000950170-21-002687 |
| us-gaap | BusinessAcquisitionsProFormaNetIncomeLoss | Business Acquisition, Pro Forma Net Income (Loss) | USD | 341.70M | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-02-14 | 0001564590-20-004667 |
| us-gaap | BusinessAcquisitionsProFormaRevenue | Business Acquisition, Pro Forma Revenue | USD | 18.50M | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-02-14 | 0001564590-20-004667 |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 5.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | CapitalLeaseObligationsNoncurrent | Capital Lease Obligations, Noncurrent | USD | 31.21M | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-040541 | |
| us-gaap | CapitalLeasesFutureMinimumPaymentsDueCurrent | Capital Leases, Future Minimum Payments Due, Next Twelve Months | USD | 1.17M | 2014-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 150.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | -60.63M | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-02-21 | 0001564590-18-002535 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 113.33M | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-03 | 0001564590-18-018979 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 164.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -272.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 149,700 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 5.83M | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | CommonStockDividendsPerShareDeclared | Common Stock, Dividends, Per Share, Declared | USD/shares | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 250.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 72.17M | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058427 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 101.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -397.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | ContractualObligation | Contractual Obligation | USD | 8.31M | 2019-12-31 | 2019 | FY | 10-K | 2020-02-14 | 0001564590-20-004667 | |
| us-gaap | ContractualObligationDueInFifthYear | Contractual Obligation, to be Paid, Year Five | USD | 62,000 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | ContractualObligationDueInFourthYear | Contractual Obligation, to be Paid, Year Four | USD | 62,000 | 2016-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 | |
| us-gaap | ContractualObligationDueInNextTwelveMonths | Contractual Obligation, to be Paid, Year One | USD | 30.41M | 2020-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 | |
| us-gaap | ContractualObligationDueInSecondYear | Contractual Obligation, to be Paid, Year Two | USD | 854,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 | |
| us-gaap | ContractualObligationDueInThirdYear | Contractual Obligation, to be Paid, Year Three | USD | 62,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-02-21 | 0001564590-18-002535 | |
| us-gaap | ContractWithCustomerAssetNet | Contract with Customer, Asset, after Allowance for Credit Loss | USD | 2.98M | 2018-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 | |
| us-gaap | ContractWithCustomerLiability | Contract with Customer, Liability | USD | 1.24M | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-03 | 0001564590-18-018979 | |
| us-gaap | ContractWithCustomerLiabilityCurrent | Contract with Customer, Liability, Current | USD | 4.44M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-07-29 | 0000950170-22-013411 | |
| us-gaap | ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination | Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination | USD | 2.53M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | 129.36M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 19.60M | 2014-02-05 | 2014 | Q3 | 10-Q | 2014-11-10 | 0001564590-14-005413 | |
| us-gaap | CostOfGoodsAndServicesSold | Cost of Goods and Services Sold | USD | 1.22M | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-02 | 0001564590-19-028087 |
| us-gaap | CostOfGoodsSold | Cost of Goods Sold (Deprecated 2018-01-31) | USD | 225,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 4.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | DebtSecuritiesAvailableForSaleGainLoss | Debt Securities, Available-for-sale, Gain (Loss) | USD | 0 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058427 |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | -16.24M | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-02-14 | 0001564590-20-004667 |
| us-gaap | DeferredForeignIncomeTaxExpenseBenefit | Deferred Foreign Income Tax Expense (Benefit) | USD | 1.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | -10.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 35.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredIncomeTaxLiabilitiesNet | Deferred Income Tax Liabilities, Net | USD | 21.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 200,000 | 2015-07-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | DeferredRentCreditCurrent | Deferred Rent Credit, Current | USD | 723,000 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | 2.00M | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | DeferredTaxAssetsEquityMethodInvestments | Deferred Tax Assets, Equity Method Investments | USD | 8.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 1.36B | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 34.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 33.31M | 2019-12-31 | 2019 | FY | 10-K | 2020-02-14 | 0001564590-20-004667 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 6.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 511.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsDomestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | USD | 4.00M | 2012-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwards | Deferred Tax Assets, Tax Credit Carryforwards | USD | 426.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | USD | 34.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 1.35B | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 29.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | DeferredTaxLiabilitiesNoncurrent | Deferred Tax Liabilities, Net, Noncurrent | USD | 33.31M | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001564590-20-022136 | |
| us-gaap | DefinedContributionPlanAdministrativeExpenses | Defined Contribution Plan, Administrative Expense | USD | 123,000 | 2015-01-01 | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-12 | 0001564590-15-003978 |
| us-gaap | DefinedContributionPlanCostRecognized | Defined Contribution Plan, Cost | USD | 10.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 25.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage | Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) | USD | 119.40M | 2014-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 | |
| us-gaap | DividendsPreferredStock | Dividends, Preferred Stock | USD | 4.30M | 2014-01-06 | 2014-02-05 | 2014 | Q2 | 10-Q | 2014-08-11 | 0001564590-14-003472 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -3.89 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -4.45 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-07-29 | 0000950170-22-013411 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -3.89 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.007 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.254 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | 0.051 | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-02-14 | 0001564590-20-004667 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | USD | 5.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | pure | -0.009 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary | Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent | pure | 0.022 | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | -0.004 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | pure | -0.011 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.016 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent | pure | 0.003 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount | USD | 14.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent | pure | -0.025 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.008 | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign | Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent | pure | -0.009 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Percent | pure | -0.108 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.021 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | -1.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | EffectOfExchangeRateOnCashContinuingOperations | Effect of Exchange Rate on Cash, Continuing Operations | USD | 249,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 |
| us-gaap | EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity | Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity | USD | 6.74M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 74.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount | Share-based Payment Arrangement, Amount Capitalized | USD | 2.78M | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-05 | 0001193125-25-265126 |
| us-gaap | EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) | USD | 9.00M | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | USD | 232.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | EquityMethodInvestments | Equity Method Investments | USD | 26.33M | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-040541 | |
| us-gaap | EquitySecuritiesFvNiGainLoss | Equity Securities, FV-NI, Gain (Loss) | USD | 512,000 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-05 | 0001193125-25-265126 |
| us-gaap | ExcessStockSharesAuthorized | Excess Stock, Shares Authorized | shares | 275.00M | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-10 | 0001564590-14-005413 | |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | 0 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | USD | 3.32M | 2014-01-01 | 2014-09-30 | 2015 | Q3 | 10-Q | 2015-11-10 | 0001564590-15-010240 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | USD | 3.42M | 2013-12-31 | 2015 | Q3 | 10-Q | 2015-11-10 | 0001564590-15-010240 | |
| us-gaap | FinanceLeaseInterestExpense | Finance Lease, Interest Expense | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-19 | 0000950170-25-023312 |
| us-gaap | FinanceLeaseLiability | Finance Lease, Liability | USD | 183,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeaseLiabilityCurrent | Finance Lease, Liability, Current | USD | 183,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeaseLiabilityNoncurrent | Finance Lease, Liability, Noncurrent | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDue | Finance Lease, Liability, Payment, Due | USD | 187,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueNextTwelveMonths | Finance Lease, Liability, to be Paid, Year One | USD | 187,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueYearThree | Finance Lease, Liability, to be Paid, Year Three | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueYearTwo | Finance Lease, Liability, to be Paid, Year Two | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeaseLiabilityUndiscountedExcessAmount | Finance Lease, Liability, Undiscounted Excess Amount | USD | 4,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | FinanceLeasePrincipalPayments | Finance Lease, Principal Payments | USD | 149,000 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-10-27 | 0001564590-20-047991 |
| us-gaap | FinanceLeaseRightOfUseAssetAmortization | Finance Lease, Right-of-Use Asset, Amortization | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-19 | 0000950170-25-023312 |
| us-gaap | FinanceLeaseWeightedAverageDiscountRatePercent | Finance Lease, Weighted Average Discount Rate, Percent | pure | 0.051 | 2022-12-31 | 2023 | FY | 10-K | 2024-02-21 | 0000950170-24-017879 | |
| us-gaap | FinancialLiabilitiesFairValueDisclosure | Financial Liabilities Fair Value Disclosure | USD | 32.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | FiniteLivedIntangibleAssetsAccumulatedAmortization | Finite-Lived Intangible Assets, Accumulated Amortization | USD | 21.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive | Finite-Lived Intangible Asset, Expected Amortization, after Year Five | USD | 11,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths | Finite-Lived Intangible Asset, Expected Amortization, Year One | USD | 8,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFive | Finite-Lived Intangible Asset, Expected Amortization, Year Five | USD | 7,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFour | Finite-Lived Intangible Asset, Expected Amortization, Year Four | USD | 7,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearThree | Finite-Lived Intangible Asset, Expected Amortization, Year Three | USD | 7,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo | Finite-Lived Intangible Asset, Expected Amortization, Year Two | USD | 7,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | FiniteLivedIntangibleAssetsNet | Finite-Lived Intangible Assets, Net | USD | 47,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ForeignCurrencyTransactionGainLossBeforeTax | Foreign Currency Transaction Gain (Loss), before Tax | USD | 221,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 |
| us-gaap | ForeignIncomeTaxExpenseBenefitContinuingOperations | Foreign Income Tax Expense (Benefit), Continuing Operations | USD | 4.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | GainLossOnDispositionOfIntangibleAssets | Gain (Loss) on Disposition of Intangible Assets | USD | 170.32M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 62.19M | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-03 | 0001564590-17-021336 |
| us-gaap | Goodwill | Goodwill | USD | 44.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | GoodwillAndIntangibleAssetImpairment | Goodwill and Intangible Asset Impairment | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-15 | 0000950170-22-001284 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -565.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -402.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | -6.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 4.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxExaminationPenaltiesAndInterestAccrued | Income Tax Examination, Penalties and Interest Accrued | USD | 100,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-19 | 0000950170-25-023312 | |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | -7.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability | Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability | USD | 70.50M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxPaidStateAndLocalAfterRefundReceived | IncomeTaxPaidStateAndLocalAfterRefundReceived | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 145.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount | USD | 1.30M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-19 | 0000950170-25-023312 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -120.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxReconciliationOtherReconcilingItems | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount | USD | -1.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxReconciliationTaxContingenciesForeign | Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount | USD | 5.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 12.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | 266,000 | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-040541 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 20.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | IncreaseDecreaseInAccountsReceivableRelatedParties | Increase (Decrease) in Accounts Receivable, Related Parties | USD | 125.55M | 2020-01-01 | 2020-03-31 | 2021 | Q1 | 10-Q | 2021-05-05 | 0001564590-21-023501 |
| us-gaap | IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | USD | 3.78M | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-040541 |
| us-gaap | IncreaseDecreaseInDeferredIncomeTaxes | Increase (Decrease) in Deferred Income Taxes | USD | -1.60M | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-21 | 0000950170-24-017879 |
| us-gaap | IncreaseDecreaseInDeferredLiabilities | Increase (Decrease) in Deferred Liabilities | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-19 | 0000950170-25-023312 |
| us-gaap | IncreaseDecreaseInInventories | Increase (Decrease) in Inventories | USD | 8.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | IncreaseDecreaseInOtherNoncurrentAssets | Increase (Decrease) in Other Noncurrent Assets | USD | -1.08M | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-040541 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | -12.27M | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-121679 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | -16.58M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058427 |
| us-gaap | IncreaseDecreaseInPrepaidExpensesOther | Increase (Decrease) in Prepaid Expenses, Other | USD | -2.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | IncreaseDecreaseInRestrictedCash | Increase (Decrease) in Restricted Cash | USD | -934,000 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-02-21 | 0001564590-18-002535 |
| us-gaap | IncreaseInRestrictedCash | Increase in Restricted Cash | USD | 1.20M | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | IncrementalCommonSharesAttributableToCallOptionsAndWarrants | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants | shares | 140,752 | 2018-01-01 | 2018-03-31 | 2019 | Q1 | 10-Q | 2019-05-07 | 0001564590-19-016079 |
| us-gaap | IntangibleAssetsGrossExcludingGoodwill | Intangible Assets, Gross (Excluding Goodwill) | USD | 197.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | IntangibleAssetsNetExcludingGoodwill | Intangible Assets, Net (Excluding Goodwill) | USD | 170.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | InterestAndDividendIncomeOperating | Interest and Dividend Income, Operating | USD | 242,000 | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-11 | 0001564590-14-003472 |
| us-gaap | InterestExpense | Interest Expense | USD | 318,000 | 2010-04-22 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-12 | 0001564590-14-002047 |
| us-gaap | InventoryFinishedGoods | Inventory, Finished Goods, Gross | USD | 29.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | InventoryGross | Inventory, Gross | USD | 61.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | InventoryNet | Inventory, Net | USD | 59.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | InventoryNoncurrent | Inventory, Noncurrent | USD | 2.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | InventoryRawMaterials | Inventory, Raw Materials, Gross | USD | 2.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | InventoryWorkInProcess | Inventory, Work in Process, Gross | USD | 30.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 14.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | InvestmentIncomeNetAmortizationOfDiscountAndPremium | Investment Income, Net, Amortization of Discount and Premium | USD | -1.40M | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-11 | 0001564590-14-003472 |
| us-gaap | InvestmentsFairValueDisclosure | Investments, Fair Value Disclosure | USD | 397.00M | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-05 | 0001193125-26-333233 | |
| us-gaap | LeaseAndRentalExpense | Operating Leases, Rent Expense | USD | 6.40M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 |
| us-gaap | LeaseCost | Lease, Cost | USD | 17.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 43.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 1.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 15.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 2.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 7.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 8.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 10.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 2.52M | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-040541 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 7.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | Liabilities | Liabilities | USD | 1.56B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 1.19B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 389.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | LiabilitiesFairValueDisclosureRecurring | Liabilities, Fair Value Disclosure, Recurring (Deprecated 2018-01-31) | USD | 3.42M | 2013-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 | |
| us-gaap | LongTermInvestments | Long-term Investments | USD | 5.17M | 2019-12-31 | 2020 | Q3 | 10-Q | 2020-10-27 | 0001564590-20-047991 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 13.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | 286.42M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 53.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | -71.03M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -337.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -89.48M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -395.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -245.87M | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance | Noncontrolling Interest, Increase from Subsidiary Equity Issuance | USD | 7.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 11.72M | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-03 | 0001564590-17-021336 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 375.71M | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-03 | 0001564590-21-039879 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -354.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 12.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 36.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 12.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 24.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 14.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 23.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 27.77M | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 5.96M | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 2.84M | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 2.83M | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 3.09M | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 4.59M | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueThereafter | Operating Leases, Future Minimum Payments, Due Thereafter | USD | 8.45M | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 6.40M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.1 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 24.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 41.37M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-121679 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 63.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax | USD | -5.27M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -2.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | -2.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | OtherLiabilitiesCurrent | Other Liabilities, Current | USD | 22.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 40.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | 2.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | OtherNonoperatingExpense | Other Nonoperating Expense | USD | 3.46M | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-11 | 0001564590-14-003472 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | 1.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | PaidInKindInterest | Paid-in-Kind Interest | USD | 318,000 | 2010-04-22 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-05-12 | 0001564590-14-002047 |
| us-gaap | PaymentsForProceedsFromOtherInvestingActivities | Payments for (Proceeds from) Other Investing Activities | USD | 2.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | PaymentsForRestructuring | Payments for Restructuring | USD | 30.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | PaymentsForTenantImprovements | Payments for Tenant Improvements | USD | 3.47M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 |
| us-gaap | PaymentsForUnderwritingExpense | Payments for Underwriting Expense | USD | 16.70M | 2015-07-01 | 2015-07-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | PaymentsOfDividends | Payments of Dividends | USD | 4.35M | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-11 | 0001564590-14-003472 |
| us-gaap | PaymentsOfDividendsPreferredStockAndPreferenceStock | Payments of Ordinary Dividends, Preferred Stock and Preference Stock | USD | 4.35M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | PaymentsToAcquireAvailableForSaleSecurities | Payments to Acquire Available-for-sale Securities | USD | 648.52M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-10-27 | 0001564590-20-047991 |
| us-gaap | PaymentsToAcquireAvailableForSaleSecuritiesDebt | Payments to Acquire Debt Securities, Available-for-sale | USD | 227.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | PaymentsToAcquireBusinessesNetOfCashAcquired | Payments to Acquire Businesses, Net of Cash Acquired | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-19 | 0000950170-25-023312 |
| us-gaap | PaymentsToAcquireEquityMethodInvestments | Payments to Acquire Equity Method Investments | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 |
| us-gaap | PaymentsToAcquireIntangibleAssets | Payments to Acquire Intangible Assets | USD | 5.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | PaymentsToAcquireInvestments | Payments to Acquire Investments | USD | 129.30M | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-11 | 0001564590-14-003472 |
| us-gaap | PaymentsToAcquireNotesReceivable | Payments to Acquire Notes Receivable | USD | 1.88M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-10-27 | 0001564590-20-047991 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 4.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | PreferredStockAccretionOfRedemptionDiscount | Preferred Stock, Accretion of Redemption Discount | USD | 4.43M | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | PreferredStockAmountOfPreferredDividendsInArrears | Preferred Stock, Amount of Preferred Dividends in Arrears | USD | 4.00M | 2013-01-01 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 |
| us-gaap | PreferredStockDividendsAndOtherAdjustments | Preferred Stock Dividends and Other Adjustments | USD | 4.81M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 25.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-10 | 0001564590-14-005413 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 53.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 89.01M | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 51.36M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-02-20 | 0001564590-19-003324 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised | USD | 3.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | USD | 200.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | ProceedsFromMinorityShareholders | Proceeds from Noncontrolling Interests | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ProceedsFromPaymentsForOtherFinancingActivities | Proceeds from (Payments for) Other Financing Activities | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ProceedsFromRepaymentsOfNotesPayable | Proceeds from (Repayments of) Notes Payable | USD | 100,000 | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 |
| us-gaap | ProceedsFromRoyaltiesReceived | Proceeds from Royalties Received | USD | 314.23M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 |
| us-gaap | ProceedsFromSaleOfAvailableForSaleSecurities | Proceeds from Sale of Available-for-sale Securities | USD | 40.39M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-10-27 | 0001564590-20-047991 |
| us-gaap | ProceedsFromSaleOfAvailableForSaleSecuritiesDebt | Proceeds from Sale of Debt Securities, Available-for-sale | USD | 91.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | ProceedsFromSaleOfIntangibleAssets | Proceeds from Sale of Intangible Assets | USD | 170.32M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-02-12 | 0001564590-21-005610 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -258.57M | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-03 | 0001564590-21-039879 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 380.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 231.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | PurchaseObligation | Purchase Obligation | USD | 479,000 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-10 | 0001564590-14-005413 | |
| us-gaap | RepaymentsOfNotesPayable | Repayments of Notes Payable | USD | 4.94M | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-02-14 | 0001564590-20-004667 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 508.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | ResearchAndDevelopmentInProcess | Research and Development in Process | USD | 75.03M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 |
| us-gaap | RestrictedCashAndCashEquivalents | Restricted Cash and Cash Equivalents | USD | 594,000 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 | |
| us-gaap | RestrictedCashAndCashEquivalentsAtCarryingValue | Restricted Cash and Cash Equivalents, Current | USD | 652,000 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-03 | 0001564590-18-018979 | |
| us-gaap | RestrictedCashAndCashEquivalentsNoncurrent | Restricted Cash and Cash Equivalents, Noncurrent | USD | 1.82M | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-03 | 0001564590-18-018979 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 8.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 6.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent | pure | 0.1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | RestructuringCosts | Restructuring Costs | USD | 30.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | RestructuringReserve | Restructuring Reserve | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -4.93B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 523.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 13.20M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-10-27 | 0001564590-20-047991 |
| us-gaap | SaleOfStockNumberOfSharesIssuedInTransaction | Sale of Stock, Number of Shares Issued in Transaction | shares | 706,072 | 2014-07-01 | 2014-07-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | SaleOfStockPricePerShare | Sale of Stock, Price Per Share | USD/shares | 120 | 2015-07-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | SalesRevenueGoodsNet | Sales Revenue, Goods, Net (Deprecated 2018-01-31) | USD | 1.31M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 |
| us-gaap | SalesRevenueNet | Revenue, Net (Deprecated 2018-01-31) | USD | 10.68M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-08 | 0001564590-18-011341 |
| us-gaap | SellingGeneralAndAdministrativeExpense | Selling, General and Administrative Expense | USD | 273.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 38.36M | 2018-01-01 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-03 | 0001564590-18-018979 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.65 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.018 | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.016 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.007 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 6.50M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 66.31 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 4.90M | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-21 | 0000950170-24-017879 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 1.70M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares | 1.20M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 22.92 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares | 2.90M | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 8.90M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 60.87 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 8.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 61.24 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | USD | 46.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 38.57 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 73.53 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 41.75 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | USD/shares | 13.3 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | shares | 898,924 | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding | shares | 3.83M | 2015-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 | |
| us-gaap | ShortTermInvestments | Short-term Investments | USD | 568.03M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-10-27 | 0001564590-20-047991 | |
| us-gaap | ShortTermLeaseCost | Short-term Lease, Cost | USD | 63,000 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-05-07 | 0001564590-19-016079 |
| us-gaap | StateAndLocalIncomeTaxExpenseBenefitContinuingOperations | State and Local Income Tax Expense (Benefit), Continuing Operations | USD | -3.00M | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | -376.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 3.135 | 2014-01-16 | 2014-01-17 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 129.36M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 121.71M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 |
| us-gaap | StockIssuedDuringPeriodValueOther | Stock Issued During Period, Value, Other | USD | -2.07M | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-27 | 0001564590-15-002066 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests | Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests | USD | 7.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | TreasuryStockCommonShares | Treasury Stock, Common, Shares | shares | 300,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | TreasuryStockDeferredEmployeeStockOwnershipPlan | Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares | USD | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | TreasuryStockShares | Treasury Stock, Shares | shares | 7,812 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-05 | 0000950170-23-018017 | |
| us-gaap | TreasuryStockValue | Treasury Stock, Value | USD | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 | |
| us-gaap | UndistributedEarningsOfForeignSubsidiaries | Undistributed Earnings of Foreign Subsidiaries | USD | 17.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 111.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 1.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-02-17 | 0000950170-23-003096 | |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 15.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | USD | 1.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 148.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | VariableLeaseCost | Variable Lease, Cost | USD | 5.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-18 | 0001193125-26-057329 |
| us-gaap | WarrantsNotSettleableInCashFairValueDisclosure | Warrants Not Settleable in Cash, Fair Value Disclosure | USD | 6.70M | 2014-01-30 | 2016 | FY | 10-K | 2017-02-17 | 0001564590-17-001714 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 101.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 69.72M | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-07-29 | 0000950170-22-013411 |
| us-gaap | WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation | Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation | shares | 201,033 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K | 2016-02-26 | 0001564590-16-013430 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 101.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-445718 |